Recent Updates — EDIT

Editas Medicine received Human Research Ethics Committee approval and completed the Clinical Trial Notification process with Australia’s Therapeutic Goods Administration to begin the Phase 1/2 Strive clinical trial of EDIT-401. The trial targets patients with heterozygous familial hypercholesterolemia, utilizing an in vivo gene editing approach designed to reduce LDL-cholesterol levels. The company has selected five sites across Australia and New Zealand, expecting initial safety data in the first quarter of 2027. Editas Medicine is a pioneering gene editing company focused on developing transformative medicines for serious diseases.

Editas Medicine reported a net loss of $18.2 million for Q2 2026, narrowing from $53.2 million in the prior year period. Cash and cash equivalents rose to $211.6 million following a May public offering that raised $125.0 million in gross proceeds, extending the company's capital runway into the second half of 2028. The firm announced preclinical data for EDIT-401 showing greater than 90% reductions in LDL-C and Lp(a) in non-human primates, with a Clinical Trial Notification submission planned for Australia this month to support a Phase 1/2 trial. Additionally, Elliott Levy resigned from the Board effective August 4, 2026, and Patrick Ellinor was appointed as an independent director on August 6, 2026. Editas Medicine is a gene editing company focused on developing transformative in vivo medicines for serious diseases.